Kamada Ltd. (KMDA)
Makes blood-derived medicines to prevent infectious diseases and treat immune disorders.
$7.06+0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-2.2%
The outlook
KMDA is trading well below its 50- and 200-day moving averages, sitting near the lower end of its 52-week range. Analysts unanimously rate it Strong Buy with an average price target about 84% above the current price. The stock remains neutral overall despite bullish analyst sentiment, reflecting the gap between professional forecasts and recent price action.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 4 analysts
Price trendBelow its 50- & 200-day averages
52-week range20% of the way from its 52-week low to high
Price targetAvg target +84% vs current price
Analyst price target
~12-month · 4 analysts$13.00average target+84.1% vs now
Now $7.06
Low $11.00High $15.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$407.3M
52-wk high
$9.35
52-wk low
$6.50
50-day avg
$7.39
200-day avg
$7.71
Trailing P/E
20.2